Skip to content

Overview

The Molecular Oncology Almanac (MOAlmanac) is a clinical and biological interpretation algorithm and paired knowledge base for precision oncology. The primary objective of MOAlmanac is to identify and associate molecular alterations with therapeutic sensitivity and resistance as well as disease prognosis. This is done for “first-order” genomic alterations -- individual events such as somatic variants, copy number alterations, fusions, and germline -- as well as “second-order” events -- those that are not associated with one single mutation, and may be descriptive of global processes in the tumor such as tumor mutational burden, microsatellite instability, mutational signatures, and whole-genome doubling.

The underlying database of this method is dependent on expert curation of the current body of knowledge on how molecular alterations affect clinical actionability. As the field of precision oncology grows, the quantity of research on how specific alterations affect therapeutic response and patient prognosis expands at an increasing rate. Curating the latest literature and presenting it in an accessible manner increases the abilities of clinicians and researchers alike to rapidly assess the importance of a molecular feature.

The database has been refactored to align with representation standards developed by the Global Alliance for Genomics & Health Genomic Knowledge Standards Work Stream. You can access our our version of the database and browser at https://old.moalmanac.org, which will be deprecated on March 31st, 2027.

Molecular Oncology Almanac resources

Note

We have not yet adapted the interpretation algorithm to this new schema.

Region-specific instances

Region-specific instances of the Molecular Oncology Almanac are developed with local collaborators and include regulatory and/or health system access content for their region.

Canada

https://ca.moalmanac.org

This instance contains marketing authorization approvals from Health Canada. We note that Health Canada's content is not approved for commercial use.

Ireland

https://ie.moalmanac.org

This instance of the Molecular Oncology Almanac was developed with the Culhane lab at the University of Limerick in collaboration with the Health Service Executive's National Cancer Control Programme. It contains marketing authorization approvals from the European Commission and Health Products Regulatory Agency, as well as approvals for reimbursement within the public health system from the Health Service Executive.

Citation

If you use the Molecular Oncology Almanac, please cite our publication. See Citation for the reference and for citing a specific database release.

Data access

The contents of this knowledge base can be downloaded through the database's GitHub releases or the API, particularly the statements endpoint.